 | • レポートコード：MRC2-11QY12581 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、94ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は悪性神経膠腫治療のグローバル市場について調査・分析したレポートです。種類別（化学療法、薬物）市場規模、用途別（病院、がん研究機関、診断センター、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別悪性神経膠腫治療の競争状況、市場シェア ・世界の悪性神経膠腫治療市場：種類別市場規模 2015年-2020年（化学療法、薬物） ・世界の悪性神経膠腫治療市場：種類別市場規模予測 2021年-2026年（化学療法、薬物） ・世界の悪性神経膠腫治療市場：用途別市場規模 2015年-2020年（病院、がん研究機関、診断センター、その他） ・世界の悪性神経膠腫治療市場：用途別市場規模予測 2021年-2026年（病院、がん研究機関、診断センター、その他） ・北米の悪性神経膠腫治療市場分析：米国、カナダ ・ヨーロッパの悪性神経膠腫治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの悪性神経膠腫治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の悪性神経膠腫治療市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの悪性神経膠腫治療市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Merck、Eli Lilly、AbbVie、Bristol-Myers Squibb、Genentech、Sun Pharmaceutical、BioMimetix、Cipla、Sigma-Aldrich、Panacea Biotec、Zydus Cadila ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Malignant glioma’s are one of the common sub-type of primary brain tumors which are highly invasive, aggressive and neurologically destructive tumors among the deadliest human cancers.
In the Malignant Glioma Market the largest market share is gained by the U.S. where there are large incidence and prevalence cases, followed by Europe where the major pharmaceuticals have their blockbuster drugs and include the major funding associations.
Market Analysis and Insights: Global Malignant Glioma Therapeutic Market
The global Malignant Glioma Therapeutic market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Malignant Glioma Therapeutic Scope and Market Size
Malignant Glioma Therapeutic market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Malignant Glioma Therapeutic market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Merck
Eli Lilly
AbbVie
Bristol-Myers Squibb
Genentech
Sun Pharmaceutical
BioMimetix
Cipla
Sigma-Aldrich
Panacea Biotec
Zydus Cadila
Market segment by Type, the product can be split into
Chemotherapy
Drugs
Market segment by Application, split into
Hospitals
Cancer Research Organizations
Diagnostic Centers
Other
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Malignant Glioma Therapeutic Revenue
1.4 Market by Type
1.4.1 Global Malignant Glioma Therapeutic Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Chemotherapy
1.4.3 Drugs
1.5 Market by Application
1.5.1 Global Malignant Glioma Therapeutic Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Cancer Research Organizations
1.5.4 Diagnostic Centers
1.5.5 Other
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Malignant Glioma Therapeutic Market Perspective (2015-2026)
2.2 Global Malignant Glioma Therapeutic Growth Trends by Regions
2.2.1 Malignant Glioma Therapeutic Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Malignant Glioma Therapeutic Historic Market Share by Regions (2015-2020)
2.2.3 Malignant Glioma Therapeutic Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Malignant Glioma Therapeutic Market Growth Strategy
2.3.6 Primary Interviews with Key Malignant Glioma Therapeutic Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Malignant Glioma Therapeutic Players by Market Size
3.1.1 Global Top Malignant Glioma Therapeutic Players by Revenue (2015-2020)
3.1.2 Global Malignant Glioma Therapeutic Revenue Market Share by Players (2015-2020)
3.1.3 Global Malignant Glioma Therapeutic Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Malignant Glioma Therapeutic Market Concentration Ratio
3.2.1 Global Malignant Glioma Therapeutic Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Malignant Glioma Therapeutic Revenue in 2019
3.3 Malignant Glioma Therapeutic Key Players Head office and Area Served
3.4 Key Players Malignant Glioma Therapeutic Product Solution and Service
3.5 Date of Enter into Malignant Glioma Therapeutic Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Malignant Glioma Therapeutic Historic Market Size by Type (2015-2020)
4.2 Global Malignant Glioma Therapeutic Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Malignant Glioma Therapeutic Market Size by Application (2015-2020)
5.2 Global Malignant Glioma Therapeutic Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Malignant Glioma Therapeutic Market Size (2015-2020)
6.2 Malignant Glioma Therapeutic Key Players in North America (2019-2020)
6.3 North America Malignant Glioma Therapeutic Market Size by Type (2015-2020)
6.4 North America Malignant Glioma Therapeutic Market Size by Application (2015-2020)
7 Europe
7.1 Europe Malignant Glioma Therapeutic Market Size (2015-2020)
7.2 Malignant Glioma Therapeutic Key Players in Europe (2019-2020)
7.3 Europe Malignant Glioma Therapeutic Market Size by Type (2015-2020)
7.4 Europe Malignant Glioma Therapeutic Market Size by Application (2015-2020)
8 China
8.1 China Malignant Glioma Therapeutic Market Size (2015-2020)
8.2 Malignant Glioma Therapeutic Key Players in China (2019-2020)
8.3 China Malignant Glioma Therapeutic Market Size by Type (2015-2020)
8.4 China Malignant Glioma Therapeutic Market Size by Application (2015-2020)
9 Japan
9.1 Japan Malignant Glioma Therapeutic Market Size (2015-2020)
9.2 Malignant Glioma Therapeutic Key Players in Japan (2019-2020)
9.3 Japan Malignant Glioma Therapeutic Market Size by Type (2015-2020)
9.4 Japan Malignant Glioma Therapeutic Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Malignant Glioma Therapeutic Market Size (2015-2020)
10.2 Malignant Glioma Therapeutic Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Malignant Glioma Therapeutic Market Size by Type (2015-2020)
10.4 Southeast Asia Malignant Glioma Therapeutic Market Size by Application (2015-2020)
11 India
11.1 India Malignant Glioma Therapeutic Market Size (2015-2020)
11.2 Malignant Glioma Therapeutic Key Players in India (2019-2020)
11.3 India Malignant Glioma Therapeutic Market Size by Type (2015-2020)
11.4 India Malignant Glioma Therapeutic Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Malignant Glioma Therapeutic Market Size (2015-2020)
12.2 Malignant Glioma Therapeutic Key Players in Central & South America (2019-2020)
12.3 Central & South America Malignant Glioma Therapeutic Market Size by Type (2015-2020)
12.4 Central & South America Malignant Glioma Therapeutic Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Merck
13.1.1 Merck Company Details
13.1.2 Merck Business Overview
13.1.3 Merck Malignant Glioma Therapeutic Introduction
13.1.4 Merck Revenue in Malignant Glioma Therapeutic Business (2015-2020))
13.1.5 Merck Recent Development
13.2 Eli Lilly
13.2.1 Eli Lilly Company Details
13.2.2 Eli Lilly Business Overview
13.2.3 Eli Lilly Malignant Glioma Therapeutic Introduction
13.2.4 Eli Lilly Revenue in Malignant Glioma Therapeutic Business (2015-2020)
13.2.5 Eli Lilly Recent Development
13.3 AbbVie
13.3.1 AbbVie Company Details
13.3.2 AbbVie Business Overview
13.3.3 AbbVie Malignant Glioma Therapeutic Introduction
13.3.4 AbbVie Revenue in Malignant Glioma Therapeutic Business (2015-2020)
13.3.5 AbbVie Recent Development
13.4 Bristol-Myers Squibb
13.4.1 Bristol-Myers Squibb Company Details
13.4.2 Bristol-Myers Squibb Business Overview
13.4.3 Bristol-Myers Squibb Malignant Glioma Therapeutic Introduction
13.4.4 Bristol-Myers Squibb Revenue in Malignant Glioma Therapeutic Business (2015-2020)
13.4.5 Bristol-Myers Squibb Recent Development
13.5 Genentech
13.5.1 Genentech Company Details
13.5.2 Genentech Business Overview
13.5.3 Genentech Malignant Glioma Therapeutic Introduction
13.5.4 Genentech Revenue in Malignant Glioma Therapeutic Business (2015-2020)
13.5.5 Genentech Recent Development
13.6 Sun Pharmaceutical
13.6.1 Sun Pharmaceutical Company Details
13.6.2 Sun Pharmaceutical Business Overview
13.6.3 Sun Pharmaceutical Malignant Glioma Therapeutic Introduction
13.6.4 Sun Pharmaceutical Revenue in Malignant Glioma Therapeutic Business (2015-2020)
13.6.5 Sun Pharmaceutical Recent Development
13.7 BioMimetix
13.7.1 BioMimetix Company Details
13.7.2 BioMimetix Business Overview
13.7.3 BioMimetix Malignant Glioma Therapeutic Introduction
13.7.4 BioMimetix Revenue in Malignant Glioma Therapeutic Business (2015-2020)
13.7.5 BioMimetix Recent Development
13.8 Cipla
13.8.1 Cipla Company Details
13.8.2 Cipla Business Overview
13.8.3 Cipla Malignant Glioma Therapeutic Introduction
13.8.4 Cipla Revenue in Malignant Glioma Therapeutic Business (2015-2020)
13.8.5 Cipla Recent Development
13.9 Sigma-Aldrich
13.9.1 Sigma-Aldrich Company Details
13.9.2 Sigma-Aldrich Business Overview
13.9.3 Sigma-Aldrich Malignant Glioma Therapeutic Introduction
13.9.4 Sigma-Aldrich Revenue in Malignant Glioma Therapeutic Business (2015-2020)
13.9.5 Sigma-Aldrich Recent Development
13.10 Panacea Biotec
13.10.1 Panacea Biotec Company Details
13.10.2 Panacea Biotec Business Overview
13.10.3 Panacea Biotec Malignant Glioma Therapeutic Introduction
13.10.4 Panacea Biotec Revenue in Malignant Glioma Therapeutic Business (2015-2020)
13.10.5 Panacea Biotec Recent Development
13.11 Zydus Cadila
10.11.1 Zydus Cadila Company Details
10.11.2 Zydus Cadila Business Overview
10.11.3 Zydus Cadila Malignant Glioma Therapeutic Introduction
10.11.4 Zydus Cadila Revenue in Malignant Glioma Therapeutic Business (2015-2020)
10.11.5 Zydus Cadila Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Malignant Glioma Therapeutic Key Market Segments
Table 2. Key Players Covered: Ranking by Malignant Glioma Therapeutic Revenue
Table 3. Ranking of Global Top Malignant Glioma Therapeutic Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Malignant Glioma Therapeutic Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Chemotherapy
Table 6. Key Players of Drugs
Table 7. Global Malignant Glioma Therapeutic Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 8. Global Malignant Glioma Therapeutic Market Size by Regions (US$ Million): 2020 VS 2026
Table 9. Global Malignant Glioma Therapeutic Market Size by Regions (2015-2020) (US$ Million)
Table 10. Global Malignant Glioma Therapeutic Market Share by Regions (2015-2020)
Table 11. Global Malignant Glioma Therapeutic Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 12. Global Malignant Glioma Therapeutic Market Share by Regions (2021-2026)
Table 13. Market Top Trends
Table 14. Key Drivers: Impact Analysis
Table 15. Key Challenges
Table 16. Malignant Glioma Therapeutic Market Growth Strategy
Table 17. Main Points Interviewed from Key Malignant Glioma Therapeutic Players
Table 18. Global Malignant Glioma Therapeutic Revenue by Players (2015-2020) (Million US$)
Table 19. Global Malignant Glioma Therapeutic Market Share by Players (2015-2020)
Table 20. Global Top Malignant Glioma Therapeutic Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Malignant Glioma Therapeutic as of 2019)
Table 21. Global Malignant Glioma Therapeutic by Players Market Concentration Ratio (CR5 and HHI)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Malignant Glioma Therapeutic Product Solution and Service
Table 24. Date of Enter into Malignant Glioma Therapeutic Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Malignant Glioma Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 27. Global Malignant Glioma Therapeutic Market Size Share by Type (2015-2020)
Table 28. Global Malignant Glioma Therapeutic Revenue Market Share by Type (2021-2026)
Table 29. Global Malignant Glioma Therapeutic Market Size Share by Application (2015-2020)
Table 30. Global Malignant Glioma Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 31. Global Malignant Glioma Therapeutic Market Size Share by Application (2021-2026)
Table 32. North America Key Players Malignant Glioma Therapeutic Revenue (2019-2020) (Million US$)
Table 33. North America Key Players Malignant Glioma Therapeutic Market Share (2019-2020)
Table 34. North America Malignant Glioma Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 35. North America Malignant Glioma Therapeutic Market Share by Type (2015-2020)
Table 36. North America Malignant Glioma Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 37. North America Malignant Glioma Therapeutic Market Share by Application (2015-2020)
Table 38. Europe Key Players Malignant Glioma Therapeutic Revenue (2019-2020) (Million US$)
Table 39. Europe Key Players Malignant Glioma Therapeutic Market Share (2019-2020)
Table 40. Europe Malignant Glioma Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 41. Europe Malignant Glioma Therapeutic Market Share by Type (2015-2020)
Table 42. Europe Malignant Glioma Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 43. Europe Malignant Glioma Therapeutic Market Share by Application (2015-2020)
Table 44. China Key Players Malignant Glioma Therapeutic Revenue (2019-2020) (Million US$)
Table 45. China Key Players Malignant Glioma Therapeutic Market Share (2019-2020)
Table 46. China Malignant Glioma Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 47. China Malignant Glioma Therapeutic Market Share by Type (2015-2020)
Table 48. China Malignant Glioma Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 49. China Malignant Glioma Therapeutic Market Share by Application (2015-2020)
Table 50. Japan Key Players Malignant Glioma Therapeutic Revenue (2019-2020) (Million US$)
Table 51. Japan Key Players Malignant Glioma Therapeutic Market Share (2019-2020)
Table 52. Japan Malignant Glioma Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 53. Japan Malignant Glioma Therapeutic Market Share by Type (2015-2020)
Table 54. Japan Malignant Glioma Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 55. Japan Malignant Glioma Therapeutic Market Share by Application (2015-2020)
Table 56. Southeast Asia Key Players Malignant Glioma Therapeutic Revenue (2019-2020) (Million US$)
Table 57. Southeast Asia Key Players Malignant Glioma Therapeutic Market Share (2019-2020)
Table 58. Southeast Asia Malignant Glioma Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 59. Southeast Asia Malignant Glioma Therapeutic Market Share by Type (2015-2020)
Table 60. Southeast Asia Malignant Glioma Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 61. Southeast Asia Malignant Glioma Therapeutic Market Share by Application (2015-2020)
Table 62. India Key Players Malignant Glioma Therapeutic Revenue (2019-2020) (Million US$)
Table 63. India Key Players Malignant Glioma Therapeutic Market Share (2019-2020)
Table 64. India Malignant Glioma Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 65. India Malignant Glioma Therapeutic Market Share by Type (2015-2020)
Table 66. India Malignant Glioma Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 67. India Malignant Glioma Therapeutic Market Share by Application (2015-2020)
Table 68. Central & South America Key Players Malignant Glioma Therapeutic Revenue (2019-2020) (Million US$)
Table 69. Central & South America Key Players Malignant Glioma Therapeutic Market Share (2019-2020)
Table 70. Central & South America Malignant Glioma Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 71. Central & South America Malignant Glioma Therapeutic Market Share by Type (2015-2020)
Table 72. Central & South America Malignant Glioma Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 73. Central & South America Malignant Glioma Therapeutic Market Share by Application (2015-2020)
Table 74. Merck Company Details
Table 75. Merck Business Overview
Table 76. Merck Product
Table 77. Merck Revenue in Malignant Glioma Therapeutic Business (2015-2020) (Million US$)
Table 78. Merck Recent Development
Table 79. Eli Lilly Company Details
Table 80. Eli Lilly Business Overview
Table 81. Eli Lilly Product
Table 82. Eli Lilly Revenue in Malignant Glioma Therapeutic Business (2015-2020) (Million US$)
Table 83. Eli Lilly Recent Development
Table 84. AbbVie Company Details
Table 85. AbbVie Business Overview
Table 86. AbbVie Product
Table 87. AbbVie Revenue in Malignant Glioma Therapeutic Business (2015-2020) (Million US$)
Table 88. AbbVie Recent Development
Table 89. Bristol-Myers Squibb Company Details
Table 90. Bristol-Myers Squibb Business Overview
Table 91. Bristol-Myers Squibb Product
Table 92. Bristol-Myers Squibb Revenue in Malignant Glioma Therapeutic Business (2015-2020) (Million US$)
Table 93. Bristol-Myers Squibb Recent Development
Table 94. Genentech Company Details
Table 95. Genentech Business Overview
Table 96. Genentech Product
Table 97. Genentech Revenue in Malignant Glioma Therapeutic Business (2015-2020) (Million US$)
Table 98. Genentech Recent Development
Table 99. Sun Pharmaceutical Company Details
Table 100. Sun Pharmaceutical Business Overview
Table 101. Sun Pharmaceutical Product
Table 102. Sun Pharmaceutical Revenue in Malignant Glioma Therapeutic Business (2015-2020) (Million US$)
Table 103. Sun Pharmaceutical Recent Development
Table 104. BioMimetix Company Details
Table 105. BioMimetix Business Overview
Table 106. BioMimetix Product
Table 107. BioMimetix Revenue in Malignant Glioma Therapeutic Business (2015-2020) (Million US$)
Table 108. BioMimetix Recent Development
Table 109. Cipla Business Overview
Table 110. Cipla Product
Table 111. Cipla Company Details
Table 112. Cipla Revenue in Malignant Glioma Therapeutic Business (2015-2020) (Million US$)
Table 113. Cipla Recent Development
Table 114. Sigma-Aldrich Company Details
Table 115. Sigma-Aldrich Business Overview
Table 116. Sigma-Aldrich Product
Table 117. Sigma-Aldrich Revenue in Malignant Glioma Therapeutic Business (2015-2020) (Million US$)
Table 118. Sigma-Aldrich Recent Development
Table 119. Panacea Biotec Company Details
Table 120. Panacea Biotec Business Overview
Table 121. Panacea Biotec Product
Table 122. Panacea Biotec Revenue in Malignant Glioma Therapeutic Business (2015-2020) (Million US$)
Table 123. Panacea Biotec Recent Development
Table 124. Zydus Cadila Company Details
Table 125. Zydus Cadila Business Overview
Table 126. Zydus Cadila Product
Table 127. Zydus Cadila Revenue in Malignant Glioma Therapeutic Business (2015-2020) (Million US$)
Table 128. Zydus Cadila Recent Development
Table 129. Research Programs/Design for This Report
Table 130. Key Data Information from Secondary Sources
Table 131. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Malignant Glioma Therapeutic Market Share by Type: 2020 VS 2026
Figure 2. Chemotherapy Features
Figure 3. Drugs Features
Figure 4. Global Malignant Glioma Therapeutic Market Share by Application: 2020 VS 2026
Figure 5. Hospitals Case Studies
Figure 6. Cancer Research Organizations Case Studies
Figure 7. Diagnostic Centers Case Studies
Figure 8. Other Case Studies
Figure 9. Malignant Glioma Therapeutic Report Years Considered
Figure 10. Global Malignant Glioma Therapeutic Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global Malignant Glioma Therapeutic Market Share by Regions: 2020 VS 2026
Figure 12. Global Malignant Glioma Therapeutic Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global Malignant Glioma Therapeutic Market Share by Players in 2019
Figure 15. Global Top Malignant Glioma Therapeutic Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Malignant Glioma Therapeutic as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Malignant Glioma Therapeutic Revenue in 2019
Figure 17. North America Malignant Glioma Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe Malignant Glioma Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. China Malignant Glioma Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Japan Malignant Glioma Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Southeast Asia Malignant Glioma Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. India Malignant Glioma Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Central & South America Malignant Glioma Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Bottom-up and Top-down Approaches for This Report
Figure 25. Data Triangulation
Figure 26. Key Executives Interviewed
悪性神経膠腫治療薬の世界市場（～2026年） Malignant glioma's are one of the common sub-type of primary brain tumors which are highly invasive, aggressive and neurologically destructive tumors among the deadliest human cancers. In the Malignant Glioma Market the largest market share is gained by the U.S. where there are large incidence and p…- 悪性神経膠腫の世界市場（～2026年） Malignant glioma's are one of the common sub-type of primary brain tumors which are highly invasive, aggressive and neurologically destructive tumors among the deadliest human cancers. In the Malignant Glioma Market the largest market share is gained by the U.S. where there are large incidence and p…
- 成人用悪性神経膠腫治療薬の世界市場（～2026年） Glioblastoma multiforme (GBM) is among the most difficult of tumors to treat, and despite all efforts, median overall survival remains at approximately 12 months. Malignant gliomas are included in the category of rare diseases, and the orphan drug status is granted for the drug candidates in the pip…
- 悪性中皮腫治療の世界市場（～2026年） Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium). Malignant mesothelioma is a cancer of the thin tissue (mesothelium) that lines the lung, chest wall, and abdomen. The major risk factor for mesothelioma is…
- 悪性リンパ腫の世界市場（～2026年） Cancers that start anywhere in the body’s lymphatic system are called lymphomas. If they have the ability to spread, they are called malignant. The lymphatic system runs throughout our bodies and is composed of lymphoid tissue, vessels, and fluid. Lymphoid tissue contains lymph nodes, which are part…